These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 33072089)

  • 1. Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring.
    Khoy K; Mariotte D; Defer G; Petit G; Toutirais O; Le Mauff B
    Front Immunol; 2020; 11():549842. PubMed ID: 33072089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients.
    Puñet-Ortiz J; Hervás-García JV; Teniente-Serra A; Cano-Orgaz A; Mansilla MJ; Quirant-Sánchez B; Navarro-Barriuso J; Fernández-Sanmartín MA; Presas-Rodríguez S; Ramo-Tello C; Martínez-Cáceres EM
    Cytometry B Clin Cytom; 2018 Mar; 94(2):327-333. PubMed ID: 28378895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab: Perspectives from the Bench to Bedside.
    Shirani A; Stüve O
    Cold Spring Harb Perspect Med; 2018 Dec; 8(12):. PubMed ID: 29500304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.
    Jilek S; Mathias A; Canales M; Lysandropoulos A; Pantaleo G; Schluep M; Du Pasquier RA
    Mult Scler; 2014 Jun; 20(7):837-42. PubMed ID: 24258149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
    Iannetta M; Zingaropoli MA; Bellizzi A; Morreale M; Pontecorvo S; D'Abramo A; Oliva A; Anzivino E; Lo Menzo S; D'Agostino C; Mastroianni CM; Millefiorini E; Pietropaolo V; Francia A; Vullo V; Ciardi MR
    PLoS One; 2016; 11(8):e0160277. PubMed ID: 27486658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B; Kappos L
    Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab therapy for multiple sclerosis.
    Derfuss T; Kuhle J; Lindberg R; Kappos L
    Semin Neurol; 2013 Feb; 33(1):26-36. PubMed ID: 23709210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab.
    Berger JR
    Drugs Today (Barc); 2006 Oct; 42(10):639-55. PubMed ID: 17136224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.
    Bennett JL
    Neurol Res; 2006 Apr; 28(3):291-8. PubMed ID: 16687056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of natalizumab in multiple sclerosis: current perspectives.
    Gandhi S; Jakimovski D; Ahmed R; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
    Expert Opin Biol Ther; 2016 Sep; 16(9):1151-62. PubMed ID: 27413840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab treatment of multiple sclerosis: new insights.
    Delbue S; Comar M; Ferrante P
    Immunotherapy; 2017 Jan; 9(2):157-171. PubMed ID: 28004598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
    Benkert TF; Dietz L; Hartmann EM; Leich E; Rosenwald A; Serfling E; Buttmann M; Berberich-Siebelt F
    PLoS One; 2012; 7(12):e52208. PubMed ID: 23284936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis.
    O'Connor P
    Expert Opin Biol Ther; 2007 Jan; 7(1):123-36. PubMed ID: 17150024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
    Shirani A; Stüve O
    J Immunol; 2017 Feb; 198(4):1381-1386. PubMed ID: 28167648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Natalizumab treatment in multiple sclerosis].
    Tanaka M
    Rinsho Shinkeigaku; 2015; 55(8):537-43. PubMed ID: 26156254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring.
    Alroughani RA; Aref HM; Bohlega SA; Dahdaleh MP; Feki I; Al Jumah MA; Al-Kawi MZ; Koussa SF; Sahraian MA; Alsharoqi IA; Yamout BI
    BMC Neurol; 2014 Feb; 14():27. PubMed ID: 24521176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.
    Schwab N; Schneider-Hohendorf T; Wiendl H
    Int Immunol; 2015 Jan; 27(1):47-53. PubMed ID: 25326459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V; Bramanti P; Mazzon E
    Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Natalizumab in the treatment of multiple sclerosis].
    Horga A; Horga de la Parte JF
    Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.